FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024922021> ?p ?o ?g. }

• W2024922021 endingPage "182" @default.
• W2024922021 startingPage "179" @default.
• W2024922021 abstract "Drug allergy and hypersensitivity have been recognized for decades, but there are still large gaps in our knowledge. First, new therapeutic agents have been introduced and some, such as biological agents, are inducing adverse drug reactions (ADRs). Impurities in drugs are becoming more common, because the raw materials are not always well characterized or may be fraudulent. These impurities can also cause severe ADRs. Finally, more knowledge is needed for an improved diagnosis and treatment of drug allergy and hypersensitivity. In the present issue of this Journal, new information has been gathered on drug allergy and hypersensitivity which should be put in the context of recent publications. Biologicals are a relatively new class of medicines that carry specific risk, in particular hypersensitivity and allergy (1). An important study attempted to determine the nature, frequency and timing of safety-related regulatory actions for biologics following approval in the United States and/or the European Union (2). A total of 174 biologics were approved and safety-related regulatory actions were decided for 41 (23.6%). The nature of safety problems identified after approval for biologics is often related to their immunomodulatory effect (infections) and hypersensitivity reactions. Cetuximab, a chimeric mouse-human IgG1 monoclonal antibody against the epidermal growth factor receptor, has a high prevalence of hypersensitivity reactions in some areas of the United States and has been associated with serum specific IgE for galactose-alpha-1,3-galactose (3). Positive skin tests to TNF-α blocking agents can be found in patients with local reactions at the injection site (4), suggesting an IgE-mediated mechanism. In 2008, certain lots of heparin were associated with anaphylactic like reactions resulting from contamination with oversulphated chondroitin sulphate (OSCS). Low-molecular weight heparins obtained by chemical and enzymatic depolymerization of heparin are also concerned (5). Several deaths have been reported after large doses of intravenous heparin administration. The activation of the contact system has been proposed for a potential biologic link between OSCS and the observed clinical adverse events (6-8). OSCS can directly activate the kinin–kallikrein pathway in human plasma, which can lead to the generation of bradykinin, a potent vasoactive mediator. In addition, OSCS induced generation of C3a and C5a, potent anaphylatoxins derived from complement proteins. The links between anaphylaxis and mastocytosis have been reviewed in a series of patients (9). Both adults and children with extensive skin disease with mastocytosis have an increased risk to develop severe anaphylactic reactions, including ones to drugs; thus, an emergency medicine kit with epinephrine/adrenaline is recommended for such subjects. In 2008, hypersensitivity or allergic reactions to new drugs such as oseltamivir (10) were recognized. Because anaphylactic reactions have been observed (11), the safety of traditionally prescribed drugs is debated. Contact allergy to topical antifungal agents is not uncommon (12). On the basis of the latest literature data (13), we recommend avoiding oat-containing emollients in children with atopic dermatitis. The diagnosis of drug allergy and hypersensitivity still needs to be improved. Patients with a history of penicillin allergy pose a treatment dilemma. Unnecessary avoidance of this relatively nontoxic class of drugs exposes the patient to often less effective and potentially more toxic drugs, increases healthcare costs, and contributes to the development of antibiotic resistance (14). Although many studies concerning the diagnosis of penicillin allergy have been carried out since the 1960s (15), such diagnosis is still a hot topic. Skin tests are recommended for the diagnosis of immediate-type reactions. In this issue of the Journal, it has been confirmed that benzylpenicillin skin testing is still useful in diagnosing immediate hypersensitivity to penicillins (16). However, anaphylactic reactions can occur after ß-lactam skin test (17). Therefore, a biological diagnosis of penicillin is still needed in order to reduce the frequency of such reactions and improve the sensitivity of the allergologic work-up (18). The basophil activation test is an interesting method in ß-lactam allergy diagnosis (19), but needs to be fully validated before it is proposed for routine use. Two basophil activation markers, CD63 and CD203c, can be used in the diagnosis of amoxicillin allergy (20). Administration of meropenem to penicillin-allergic patients who might benefit from this treatment is usually avoided. However, recent studies have demonstrated a very low rate of cross-reactivity between penicillins and both meropenem and imipenem in adults (21, 22). A low rate of cross-reactivity between penicillins and meropenem has also been found in children (23). Therefore, the practice of avoiding these carbapenems in subjects with IgE-mediated hypersensitivity to penicillins could be abandoned (21-23). Non-immediate reactions to ß-lactams are complex, and the diagnostic value of skin testing and drug provocation tests has been compared (24). In this issue of the Journal, Blanca et al. propose a European Network for Drug Allergy (ENDA, the European Academy of Allergology and Clinical Immunology interest group on drug hypersensitivity) updates in the diagnosis of ß-lactam allergy (25). CD69 upregulation on T cells is an in vitro marker for delayed-type drug hypersensitivity (26), but its role in daily practice needs more studies. Radiocontrast media can induce allergic reactions, and the results of a European multicentric study on skin tests are reported in this issue (27). The diagnosis of drug allergy and hypersensitivity needs to be standardized. The diagnosis of allergic reactions to many drugs has been standardized by the ENDA and standard operating procedures (SOPs) have been published. The ENDA was initiated as a FP3 EU project and has been self-sustainable following EU funding. It has always worked under the aegis of the European Academy of Allergology and Clinical Immunology. This network is unique in the world. Moreover, allergic ADRs are not easily determined and need a specific diagnostic work-up, as shown by the inaccuracy of pharmacovigilance algorithms (28). There is, therefore, a need for a specific database with SOPs on drug allergy and hypersensitivity. The GALENDA project described in this issue uses a pharmacovigilance/pharmacoepidemiology database on drug allergy/hypersensitivity – established under FileMaker® Pro 9 (Drug Allergy and Hypersensitivity Database) – and is based on a sustainable FP6 Network of excellence [Global Allergy and Asthma European Network; GA2LEN (29)] in order to obtain the optimal diagnosis of the patients using ENDA SOPs. Such database is already available online in many different languages and can be accessed using a personal login. Interacting with a pharmacovigilance network, this platform appears to be of great interest for the reporting of allergy/hypersensitivity ADRs in conjunction with other pharmacovigilance instruments. Moreover, GALENDA will use GA2LEN expertise in the dissemination of results to all stakeholders, including physicians, patients (with EFA-European Federation of Allergy and Airways Diseases Patients’ Associations), media and government officials to increase awareness and optimal reporting of drug allergy/hypersensitivity, which is often greatly underestimated and poorly reported. Aspirin hypersensitivity is still an important research field. Systemic responses have been found after aspirin bronchial challenges (30). A definitive diagnosis of aspirin-exacerbated respiratory diseases requires a positive aspirin challenge, but predicting which patients will have positive challenges is often difficult. Age under 40 years, poor sense of smell, multiple prior respiratory reactions and severe prior asthmatic reactions associated with aspirin and other NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) significantly increased the chances of a positive oral aspirin challenge (31). Triflusal (an antiplatelet drug) and etoricoxib may not be safe in patients with aspirin-exacerbated respiratory diseases (32, 33). The daily dose of aspirin in desensitization in aspirin-sensitive asthmatics with nasal polyps is still a matter of debate. In one study, it was found that aspirin desensitization followed by 300-mg aspirin daily is efficacious, whereas a daily dose of 100-mg daily is not sufficient to significantly reduce nasal and bronchial symptoms (34). The diagnosis and management of HIV drug hypersensitivity has been reviewed (35). Drug hypersensitivity reactions are an important cause of morbidity in HIV-infected patients with complex medication regimens. Correct diagnosis and management of these reactions are essential in the clinical care of HIV disease. Trimethoprim–sulfamethoxazole, abacavir, nevirapine, atazanavir and enfuvirtide can all cause hypersensitivity eruptions. In the aforesaid review (35), the authors discuss the evidence for immunological mechanisms of hypersensitivity reactions to HIV drugs, the clinical characteristics of these reactions, and the guidelines that currently exist for their identification and management. Many anaphylactic reactions are caused by drugs (36), in particular in children (37). The treatment of anaphylaxis has been widely reviewed in recent years, and in particular in this Journal (38, 39). In this issue, Sheikh et al. (40) perform a systematic review, using the Cochrane system to assess the role of adrenalin for the treatment of anaphylaxis. Research questions are of great importance for understanding and managing drug allergy and hypersensitivity. These questions have been addressed in this Journal recently (41-44), and may form the basis for future collaborative research." @default.
• W2024922021 created "2016-06-24" @default.
• W2024922021 creator A5024644149 @default.
• W2024922021 creator A5025157783 @default.
• W2024922021 creator A5040116193 @default.
• W2024922021 date "2009-01-21" @default.
• W2024922021 modified "2023-10-12" @default.
• W2024922021 title "Drug allergy and hypersensitivity: still a hot topic" @default.
• W2024922021 cites W1520265077 @default.
• W2024922021 cites W1532823377 @default.
• W2024922021 cites W1568696684 @default.
• W2024922021 cites W1582918125 @default.
• W2024922021 cites W1755124412 @default.
• W2024922021 cites W1851557299 @default.
• W2024922021 cites W1969737490 @default.
• W2024922021 cites W1975019168 @default.
• W2024922021 cites W1975838351 @default.
• W2024922021 cites W1981639602 @default.
• W2024922021 cites W1982103573 @default.
• W2024922021 cites W1984414225 @default.
• W2024922021 cites W1988726966 @default.
• W2024922021 cites W1997969364 @default.
• W2024922021 cites W2002473719 @default.
• W2024922021 cites W2003538275 @default.
• W2024922021 cites W2005427839 @default.
• W2024922021 cites W2005769970 @default.
• W2024922021 cites W2011477740 @default.
• W2024922021 cites W2013067549 @default.
• W2024922021 cites W2025799230 @default.
• W2024922021 cites W2035549450 @default.
• W2024922021 cites W2047526468 @default.
• W2024922021 cites W2056437608 @default.
• W2024922021 cites W2056955889 @default.
• W2024922021 cites W2056980240 @default.
• W2024922021 cites W2071070981 @default.
• W2024922021 cites W2081848037 @default.
• W2024922021 cites W2081936425 @default.
• W2024922021 cites W2086283050 @default.
• W2024922021 cites W2090045932 @default.
• W2024922021 cites W2090645243 @default.
• W2024922021 cites W2111016182 @default.
• W2024922021 cites W2111356739 @default.
• W2024922021 cites W2140035322 @default.
• W2024922021 cites W2141186862 @default.
• W2024922021 cites W2141451265 @default.
• W2024922021 cites W2147058510 @default.
• W2024922021 cites W2157584018 @default.
• W2024922021 cites W2507193333 @default.
• W2024922021 cites W4238028096 @default.
• W2024922021 cites W4243807236 @default.
• W2024922021 doi "https://doi.org/10.1111/j.1398-9995.2008.01960.x" @default.
• W2024922021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19178397" @default.
• W2024922021 hasPublicationYear "2009" @default.
• W2024922021 type Work @default.
• W2024922021 sameAs 2024922021 @default.
• W2024922021 citedByCount "12" @default.
• W2024922021 countsByYear W20249220212015 @default.
• W2024922021 countsByYear W20249220212017 @default.
• W2024922021 countsByYear W20249220212019 @default.
• W2024922021 countsByYear W20249220212021 @default.
• W2024922021 countsByYear W20249220212022 @default.
• W2024922021 countsByYear W20249220212023 @default.
• W2024922021 crossrefType "journal-article" @default.
• W2024922021 hasAuthorship W2024922021A5024644149 @default.
• W2024922021 hasAuthorship W2024922021A5025157783 @default.
• W2024922021 hasAuthorship W2024922021A5040116193 @default.
• W2024922021 hasConcept C16005928 @default.
• W2024922021 hasConcept C203014093 @default.
• W2024922021 hasConcept C207480886 @default.
• W2024922021 hasConcept C2779060952 @default.
• W2024922021 hasConcept C2780035454 @default.
• W2024922021 hasConcept C71924100 @default.
• W2024922021 hasConcept C98274493 @default.
• W2024922021 hasConceptScore W2024922021C16005928 @default.
• W2024922021 hasConceptScore W2024922021C203014093 @default.
• W2024922021 hasConceptScore W2024922021C207480886 @default.
• W2024922021 hasConceptScore W2024922021C2779060952 @default.
• W2024922021 hasConceptScore W2024922021C2780035454 @default.
• W2024922021 hasConceptScore W2024922021C71924100 @default.
• W2024922021 hasConceptScore W2024922021C98274493 @default.
• W2024922021 hasIssue "2" @default.
• W2024922021 hasLocation W20249220211 @default.
• W2024922021 hasLocation W20249220212 @default.
• W2024922021 hasOpenAccess W2024922021 @default.
• W2024922021 hasPrimaryLocation W20249220211 @default.
• W2024922021 hasRelatedWork W1507998839 @default.
• W2024922021 hasRelatedWork W1621145776 @default.
• W2024922021 hasRelatedWork W1985980299 @default.
• W2024922021 hasRelatedWork W2021177014 @default.
• W2024922021 hasRelatedWork W2411369533 @default.
• W2024922021 hasRelatedWork W2970951906 @default.
• W2024922021 hasRelatedWork W3089896383 @default.
• W2024922021 hasRelatedWork W3196832741 @default.
• W2024922021 hasRelatedWork W4220703223 @default.
• W2024922021 hasRelatedWork W4387024790 @default.
• W2024922021 hasVolume "64" @default.
• W2024922021 isParatext "false" @default.
• W2024922021 isRetracted "false" @default.

• next